Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
779
Shown on this page
12
Current sort
Recently updated
Campus scope
Weill Cornell Medicine, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Weill Cornell Medicine, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 217–228 of 779 matching trials with a site at Weill Cornell Medicine, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT06169215
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Selinexor
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
27
States / cities
Irvine, California • Laguna Hills, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Recruiting Phase 3 Interventional

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748
Status at this site: Recruiting
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
56
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Active, not recruiting Phase 2 Interventional

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

NCT04679012
Site status not listed — check the official record
View directory record Official record
Conditions
Richter Syndrome, Chronic Lymphocytic Leukemia
Interventions
Polatuzumab Vedotin, Rituximab, Etoposide, Prednisone, Cyclophosphamide, Hydroxydaunomycin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Active, not recruiting Not applicable Interventional

A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

NCT06455098
Site status not listed — check the official record
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
OMNYPULSE™ Catheter with the TRUPULSE Generator
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
39
States / cities
Phoenix, Arizona • Burlingame, California • Larkspur, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Recruiting Phase 3 Interventional

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222
Status at this site: Recruiting
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
59
States / cities
Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

NCT05610163
Site status not listed — check the official record
View directory record Official record
Conditions
Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions
Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
679
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients

NCT05587517
Site status not listed — check the official record
View directory record Official record
Conditions
Grief, Trauma, Psychotherapy, Critical Care
Interventions
EMPOWER, Supportive Conversation
Behavioral · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244
Status at this site: Recruiting
View directory record Official record
Conditions
Healthy
Interventions
Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix
Biological
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 49 Years
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
120
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Recruiting Phase 3 Interventional

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

NCT07100990
Status at this site: Recruiting
View directory record Official record
Conditions
Optic Neuritis, Myelitis, Myelitis, Transverse
Interventions
High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Recruiting Phase 3 Interventional

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774
Status at this site: Recruiting
View directory record Official record
Conditions
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Muvalaplin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
159
States / cities
Birmingham, Alabama • Apache Junction, Arizona • Gilbert, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Recruiting Phase 3 Interventional

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242
Status at this site: Recruiting
View directory record Official record
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 12:38 PM EDT
Recruiting Not applicable Interventional

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

NCT05172960
Status at this site: Recruiting
View directory record Official record
Conditions
Aortic Stenosis, Severe
Interventions
SAPIEN X4 THV, SAPIEN X4S
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
58
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 12:38 PM EDT

About this Weill Cornell Medicine institution page

What this page lists
ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.